Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adderall XR Augmentation of rTMS for Major Depressive Disorder
NCT04509102Phase 1Enrolling by invitation
- Sponsor
- University of California, Los Angeles
- Start
- Sep 2021
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in major depressive disorder (MDD) comparing Active (Adderall XR) with Placebo (2 arms). Primary endpoint: Mean Percent Change in Self-rated Inventory of Depressive Symptoms at 4 weeks. Started Sep 2021; status: enrolling by invitation.
02
Drugs
mixed salts of a single-entity amphetamine product extended-release capsules
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04509102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04509102.